Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks

被引：0
|
作者：
Yale, Jean-Francois
Bakris, George
Cariou, Bertrand
Iglesias, Javier Nieto
Wajs, Ewa
Figueroa, Katherine
Jiang, Joel
Usiskin, Keith
Meininger, Gary
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1075-P
引用
收藏
页码：A277 / A278
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks
    Stenloef, Kaj
    Cefalu, William T.
    Kim, Kyoung-Ah
    Jodar, Esteban
    Alba, Maria
    Edwards, Robert
    Tong, Cindy
    Canovatchel, William
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A303 - A303
  • [2] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks
    Forst, Thomas
    Guthrie, Robert
    Goldenberg, Ronald
    Yee, Jacqueline
    Vijapurkar, Ujjwala
    Meininger, Gary
    Stein, Peter
    [J]. DIABETES, 2013, 62 : A284 - A284
  • [3] Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus and chronic kidney disease over 52 weeks
    Nieto, J.
    Yale, J. -F.
    Bakris, G.
    Cariou, B.
    Wajs, E.
    Figueroa, K.
    Jiang, J.
    Usiskin, K.
    Meininger, G.
    [J]. DIABETOLOGIA, 2013, 56 : S381 - S381
  • [4] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
    Lavalle Gonzalez, Fernando J.
    Januszewicz, Andrzej
    Davidson, Jaime
    Qiu, Rose
    Tong, Cindy
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A61 - A61
  • [5] Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
    Yale, J. -F.
    Bakris, G.
    Cariou, B.
    Nieto, J.
    David-Neto, E.
    Yue, D.
    Wajs, E.
    Figueroa, K.
    Jiang, J.
    Law, G.
    Usiskin, K.
    Meininger, G.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (10): : 1016 - 1027
  • [6] Long-term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks
    Bode, Bruce
    Stenlof, Kaj
    Harris, Stewart
    Sullivan, Daniel
    Fung, Albert
    Usiskin, Keith
    [J]. DIABETES, 2014, 63 : A71 - A71
  • [7] Efficacy and Safety of Canagliflozin (CANA) in Japanese Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Diet and Exercise over 24 Weeks
    Inagaki, Nobuya
    Kondo, Kazuoki
    Yoshinari, Toru
    Maruyama, Nobuko
    Takahashi, Nahoko
    Susuta, Yutaka
    Kuki, Hideki
    [J]. DIABETES, 2014, 63 : A266 - A266
  • [8] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nyirjesy, Paul
    Sobel, Jack
    Fung, Albert
    Gassmann-Mayer, Cristiana
    Ways, Kirk
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A276 - A276
  • [9] Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney disease during treatment
    Roussel, R.
    de Zeeuw, D.
    Law, G.
    Meininger, G.
    [J]. DIABETOLOGIA, 2014, 57 : S322 - S323
  • [10] Urinary Tract Infection (UTI) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nicolle, Lindsay E.
    Capuano, George
    Fung, Albert
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A296 - A296
12345